MT-45 (IC-6) is an opioid analgesic drug invented in the 1970s by Dainippon Pharmaceutical Co. It is chemically a 1-substituted-4-(1,2-diphenylethyl)piperazine derivative, which is structurally unrelated to most other opioid drugs. Racemic MT-45 has around 80% the potency of morphine, with almost all opioid activity residing in the (S) enantiomer (the opposite stereochemistry from the related drug lefetamine). It has been used as a lead compound from which a large family of potent opioid drugs have been developed, including full agonists, partial agonists, and antagonists at the three main opioid receptor subtypes.
Recreational use of MT-45 has been associated with hearing loss and unconsciousness. MT-45 became a class A drug in the UK on 11 March 2015. MT-45 is banned in the Czech Republic. The Canadian Controlled Drugs and Substances Act was amended in 2016 to include the substance as a Schedule I substance. Possession without legal authority can result in maximum 7 years imprisonment. Further, Health Canada amended the Food and Drug Regulations in May 2016 to classify MT-45 as a restricted drug. Only those with a law enforcement agency, a person with an exemption permit or institutions with Minister’s authorization may possess the drug in Canada.
Product Number: MTE10186
Cross Reactivity
Analyte | LOD | Matrices | Compounds | Cross Reactivity % |
---|---|---|---|---|
MT-45 | 5 ng/mL | Whole Blood, Post Mortem Blood, Urine | MT-45 | 100 |
3-hydroxy MT-45 | 139.3 |